The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.
This innovative biotech offers investors an intriguing play on the medical marijuana business.
In the first quarter of the year we've seen some high-profile IPOs. But they're not all created equal. Here's what investors should keep an eye out for ... and avoid.
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.